All In Biotech

Drug Trial Radar · NCT07587047

Adia Med of Winter Park LLC Lower Back Pain Research Study

A Randomized, Placebo-Controlled, Single-Blind, Crossover Study to Evaluate the Safety and Preliminary Efficacy of a Single Intravenous AdiaVita (Umbilical Cord Blood - Stem Cells and Exosomes) Infusion in Adults With Chronic Mechanical Lower Back Pain

Last checked: Nov 20, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Jun 16, 2026

Primary completion

Jan 2028

Study completion Jan 2028

Sponsor

Lead sponsor
Adia Med of Winter Park LLCAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical study is to evaluate the safety and preliminary efficacy of an investigational umbilical cord blood-derived stem cell and exosome infusion in adults with chronic lower back pain associated with degenerative spine disease. The primary questions this study aims to answer are whether the investigational infusion is safe and well tolerated and whether treatment may reduce pain and improve physical function and quality of life. Researchers will compare the investigational infusion to a placebo (saline solution) to evaluate potential treatment effects in participants with chronic mechanical lower back pain. Participants will receive either the investigational infusion or placebo intravenously during a study visit, complete pain, disability, and quality-of-life assessments, undergo magnetic resonance imaging (MRI) and laboratory testing, and attend follow-up evaluations over a 6-month period. Participants initially assigned to placebo may later receive the investigational treatment during an open-label crossover phase of the study.

Conditions

  • Chronic Mechanical Lower Back Pain
  • Lower Back Pain
  • Chronic Lower Back Pain

Interventions

  • Umbilical Cord Blood-Derived Stem Cells and ExosomesBiological

    Intravenous infusion of cryopreserved allogeneic umbilical cord blood-derived product containing viable mononuclear cells (including hematopoietic and mesenchymal stem/stromal cells) and exosomes.

  • Placebo IVOther

    Matched placebo intravenous infusion (administered in the same volume and manner as stem cell and exosome product).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Average Low Back Pain Intensity From Baseline to Month 3Time frame: Baseline to Month 3
  2. Change in Functional Disability From Baseline to Month 3Time frame: Baseline to Month 3

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Adia Med Of Winter Park

    Winter Park, Florida · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.